AAA
DNTH icon

Affinity Asset Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Affinity Asset Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4M Buy
350,000
+235,000
+204% +$13.6M 1.52% 19
2025
Q4 		$4.74M Sell
115,000
-147,100
-56% -$5.7M 0.27% 67
2025
Q3 		$10.3M Buy
+262,100
New +$6.7M 0.9% 33

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Affinity Asset Advisors's DNTH Position: Q1 2026 in Review

Affinity Asset Advisors increased its Dianthus Therapeutics (DNTH) stake by 204% in Q1 2026, buying an estimated $13.6M and bringing the position to 350,000 shares worth $29.4M. The position accounts for 1.52% of the portfolio, ranked #19.

Affinity Asset Advisors first reported a position in DNTH in Q3 2025 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Affinity Asset Advisors held 350,000 shares of Dianthus Therapeutics worth $29.4M as of Q1 2026.
  • Affinity Asset Advisors bought 235,000 Dianthus Therapeutics shares in Q1 2026, an estimated $13.6M.
  • Dianthus Therapeutics made up 1.52% of Affinity Asset Advisors's portfolio in Q1 2026, its #19 holding.
  • Affinity Asset Advisors first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.